1. Introduction {#sec1}
===============

Arsenic (As) is a widely distributed element in the environment that is mainly transported by water. The arsenic species in polluted water are the inorganic trivalent form (arsenite) and the pentavalent form (arsenate); the trivalent form exhibits higher toxicity than does the pentavalent form. Arsenic has been associated with cardiovascular diseases, diabetes, neurological manifestations, and many cancers such as those of skin, bladder, liver, lung, kidney, and prostate \[[@B1]--[@B3]\]. Cumulative, long-term exposure to arsenic could cause dose-dependent, nonspecific chronic effects in the organs. Although the mechanism is not yet clear, arsenic compounds are designated as carcinogens by the International Agency for Research on Cancer (IARC).

Skin cancer is one of the most common arsenic-induced cancers. Among the types of skin cancers, squamous cell carcinoma and basal cell carcinoma, but not melanoma, are associated with the presence of arsenic in drinking water \[[@B4]\]. Previous studies showed that arsenic may contribute to the progression of skin cancer in association with carcinogen partner such as sunlight. A strong dose-response relationship between arsenic exposure and skin lesions has been consistently observed \[[@B5]\]. However, even among people with a relatively high arsenic exposure for many years, less than 30% of exposed victims were affected with skin lesions in Taiwan \[[@B6]\]. Genetic factors, nutritional status, ethnicity, an early age of exposure and variations in arsenic biotransformation are all potentially responsible for differences in individual susceptibility to arsenic-induced skin carcinogenesis.

Reduction of arsenic is associated with the production of reactive oxygen species (ROS) \[[@B7]\]. ROS such as hydrogen peroxide and hydroxyl radical could directly or indirectly degrade cellular compounds. Arsenic has been demonstrated to induce ROS formation in many cell types and thus cause DNA damage, protein modification, and lipid peroxidation in these cells \[[@B8]\]. An excess of ROS plays a role for certain cancer development. The theory that arsenic induces ROS to cause carcinogenicity could partially explain the high incidence of lung, bladder, and skin cancers \[[@B9]\].

Heme oxygenase (HO-1) and NAD(P)H:quinone oxidoreductase 1 (NQO1) are genes involved in the reduction of iron-mediated ROS. Increased oxidative stress will promote nuclear factor erythroid 2-related factor 2 (Nrf2) accumulation, which activates transcription of HO-1 and NQO-1. HO-1 catalyzes the rate-limiting step in heme degradation and is rapidly upregulated by ROS or heavy metals. The numbers of (GT)n repeats in promoter region are inversely related to its enzyme activity. Our previous studies have shown that shorter (GT)n repeats of HO-1 were associated with reduced arsenic-associated carotid atherosclerosis and cardiovascular mortality \[[@B10], [@B11]\]. One meta-analysis suggests that longer HO-1 (GT)n repeats are potential genetic factors for developing squamous cell carcinoma \[[@B12]\]. NQO1 has the multiple roles in the protection against cancer development including superoxide scavenging, quinones detoxification, tumor suppressor proteins stabilization, and microtubules stabilization. The C609T (Pro187Ser) polymorphism has been shown to have strong impact on gene product stability and enzyme activity. One comprehensive meta-analysis involving 92 studies suggests that C609T is an important genetic factor for overall cancer risk as well as bladder and gastric cancer risk \[[@B13]\]. Microsomal epoxide hydrolase (EPHX) is responsible for the hydrolysis of various epoxides. EPHX breaks the three-membered epoxide ring structure to form a less-reactive diol that can be more readily excreted. The T337G Tyr113His and A415G His139Arg polymorphisms have been reported associated with 40% decreased and 25% increased enzyme activity \[[@B14]\].

DNA repair is essential for maintaining genomic stability. Polymorphisms in DNA repair genes may result in differential DNA repair activity and further contribute to individual susceptibility for various cancer developments. Base excision repair (BER) is responsible for repairing oxidative DNA damage and single-strand breaks. The X-ray repair cross complementing group 1 (XRCC1) gene is involved in the BER pathway. Several SNPs in the XRCC1 have been reported for amino acid changes, including Arg399Gln G\>A and Arg280His G\>A. Several epidemiological studies and one meta-analysis suggest that these two SNPs are associated with the risk of nonmelanoma skin cancer \[[@B15]--[@B17]\]. Human 8-oxoguanine DNA*N*-glycosylase 1(*hOGG1*), also involved in BER pathway, is responsible for repairing DNA damage 8-oxo-7,8-dihydroguanine. There is a C\>G transversion in exon 7, resulting in an amino acid change from serine to cysteine (Ser326Cys). The variant of this SNP is associated with an impairment of DNA glycosylase activity \[[@B18]\]. hOGG1 Ser326Cys polymorphism has been reported associated with various types of malignancy including lung, esophageal, bladder, and prostate cancer \[[@B19]--[@B21]\].

Nucleotide excision repair (NER) is responsible for the removal of UV protoproducts and bulky adducts. Xeroderma pigmentosum (XP) patients, deficient in the NER, have a strikingly increased (\>1000-fold) risk of skin cancer. Xeroderma pigmentosum group D (*XPD*) involved in NER and mutations in the gene leads to NER defect \[[@B22]\]. It has been consistently documented that nonsynonymous polymorphism at XPD codon 156 is associated with NMSC \[[@B23], [@B24]\]. One study has also shown that XPD polymorphisms modify the association between arsenic exposure and NMSC \[[@B25]\].

In the present study, we aimed to examine the association of potential genetic factors with arsenic-induced skin cancers. This hospital-based case control study was conducted in southwestern Taiwan where high arsenic exposure was found in the drinking water. The polymorphisms of interests were classified into three groups according to their functions: (i) xenobiotic metabolic genes: glutathione S-transferases (GSTs) M1, T1, and P1 Ile105Val (rs1695); (ii) reactive oxidative stress (ROS) related genes: NQO1 C609T (rs1800566), EPHX1 Tyr113His (rs1051740) and His139Arg (rs2234922), and HO-1 5′-franking region GT repeats; (iii) DNA repair genes: XRCC1 Arg280His (rs25489) and Arg399Gln (rs25487), XPD C156A (rs238406), hOGG1 Ser326Cys (rs1052133), and ataxia-telangiectasia mutated (ATM) IVS48 +238C\>G (rs609429).

2. Materials and Methods {#sec2}
========================

2.1. Study Population {#sec2.1}
---------------------

The study population was chosen as previous studies \[[@B11], [@B12]\]. Three villages, Ho-Mei, Fu-Hsing, and Hsing-Ming, of Putai Township along the southwest coast of Taiwan were selected as the study area. The names and addresses of all adult residents in the three villages under study were obtained from census records at the local census registration office, where sociodemographic characteristics including birth date, gender, marital status, educational level, and occupation of all the members of every household were registered and updated annually. From a total of 2258 residents aged 30 years or above who were registered within the study area, only 1571 individuals who resided at least 5 days a week in the village were recruited into the study. All the subjects were of the same Ming-Nang ethnicity. Between 1989 and 1996, about 1081 study subjects underwent six community health examinations. At this time, biological specimens were collected including blood buffy coat. About 30% of subjects refused to give the blood samples or had inadequate DNA samples. There were no differences in characteristics between the subjects with and without blood samples based on age, gender, educational level, and smoking status. A total of 764 (71%) adequate lymphocyte DNA samples were available for future study. The skin lesions of all participants were clinically diagnosed by the experienced dermatologists from Kaohsiung Medical University. Three age (±5) and gender matched controls for each case were selected from the study subjects with DNA available and with no history of any malignancy. Finally, a total of 70 pathological-confirmed skin cancer patients, including 57 patients with Bowen\'s diseases, 4 with basal cell carcinoma (BCC), 5 with squamous cell carcinoma (SCC), and 4 with Bowen\'s disease and BCC, and 210 age and gender matched controls were recruited for this study.

Each study participant was personally interviewed by a public health nurse. Information obtained from the interview included the history of drinking high arsenic artesian water, residential history, sociodemographic characteristics, lifestyle variables such as alcohol consumption, cigarette smoking, and dietary consumption frequency, and personal and family medical histories. The cumulative arsenic exposure index in ppm-year was defined as the sum of products by multiplying the arsenic concentration in well water by the duration of water consumption for consecutive periods of time as resident in each of the villages. This study was approved by the Institutional Review Board of the National Taiwan University College of Public Health, and the informed consent of all participants was obtained.

2.2. DNA Extraction and Genotyping {#sec2.2}
----------------------------------

Buffy coat was isolated from 10 mL of blood using heparin and stored at −70°C until genomic DNA was extracted according to the manufacturer\'s protocol. All genetic polymorphisms of candidate genes, except GST M1, T1, and HO-1, were detected by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) analysis. The restriction enzymes used in the RFLP analysis are shown in [Table 1](#tab1){ref-type="table"}. In brief, PCR products were digested by the restriction enzyme overnight and then separated on 2% agarose gels. The primers used to detect polymorphisms of GST M1, T1, and HO-1 are also shown in [Table 1](#tab1){ref-type="table"}. PCR analysis was carried out in 2 *μ*L of diluted DNA, 1 *μ*L of each primer at 5 *μ*M, 1 *μ*L of 2.5 mM dNTPs, and 0.16 units of Taq polymerase. Cycling conditions are as follows: denaturation at 94°C for 4 minutes, 35 cycles of denaturation at 94°C for 40 seconds, annealing at 55°C for 30 seconds, elongation at 72°C for 40 seconds, and finally 72°C for 10 minutes as the last step. Null types of GST M1 and T1 would not have produced amplified products, whereas nonnull types would generate the PCR products. Thus, the different types of these two polymorphisms could be identified. The 5′-site of the HO-1 forward primer was labeled with FAM fluorescence dye in [Table 1](#tab1){ref-type="table"}. PCR products were sequenced using the DNA sequencer (ABI prism 377) and then analyzed with the GeneScan software (Applied Biosystems, Foster City, CA, USA). The number of (GT)n in the HO-1 gene with more than 29 repeats was identified as long (L), and those with less than 28 repeats were identified as short (S).

2.3. Statistical Analysis {#sec2.3}
-------------------------

Distribution of cumulative arsenic exposure and monomethylarsonic acid (MMA) percentage between cases and controls was compared using the chi-square (*χ* ^2^) test. Genotypic frequencies were estimated by direct counting and *χ* ^2^ tests were utilized to determine the significance of the association between groups with a contingency table. The risk for skin cancers associated with the genotypes was estimated as an odds ratio (OR) and 95% confidence interval (CI) by logistic regression with adjustment for the effect of possible confounders such as age, gender, cumulative arsenic exposure, and MMA percentage. We performed gene-gene interaction separately for (1) the polymorphisms in GSTs family; (2) reactive oxidative stress related polymorphisms; (3) DNA repair related polymorphisms; and (4) the combination of the polymorphisms which showed significant association with the disease based on univariate analysis. All statistical tests were performed using SAS statistical software (version 9.3, SAS Institute Inc., Cary, NC, USA) on two-sided probabilities.

3. Results {#sec3}
==========

The mean of age and the distributions of gender, cumulative arsenic exposure, and MMA percentage were presented in [Table 2](#tab2){ref-type="table"}. Age and gender was not different among cases and controls. High cumulative arsenic exposure and high MMA percentage were associated with an increased skin cancer risk. Odds ratios (95% CIs) were 1.00 (referent), 3.55 (1.14--11.06), and 5.25 (1.72--16.05) for cumulative arsenic concentrations of \<10.0, 10.0--19.9, 20.0+ ppm-years, respectively. *P* value for trend test was 0.0028. The subjects with higher MMA percentage (\>13.81%) had a 101% increased disease risk when compared to the ones with lower percentage (OR = 2.01, 95% CI: 1.09--3.73).

In the univariate analysis of genetic polymorphisms ([Table 3](#tab3){ref-type="table"}), GSTT1, EPHX1 exon 3, and XPD exon 6 showed significantly higher risks. The OR of GSTT1 null genotype was 1.74 (1.00--3.02). The ORs of EPHX1 exon 3 T/C and C/C polymorphisms were 3.74 (1.20--11.66) and 2.58 (0.85--7.85), respectively. When the T/C and C/C groups were combined, the OR compared with the T/T group was 2.99 (1.01--8.83). In addition, the ORs of A/C and A/A polymorphisms in XPD exon 6 were found to be 1.96 (0.91--4.22) and 2.24 (0.93--5.40), though the difference was not statistically significant. Statistical significance at borderline level was observed after the two groups were combined, with an OR of 2.04 (0.99--4.27). However, none of the polymorphisms in this study showed significant association with the disease if multiple comparison issue was considered.

In the multivariate analysis adjusted for age, gender, cumulative arsenic exposure, and MMA percentage, all the OR values were reduced ([Table 4](#tab4){ref-type="table"}). No significant differences were found in EPHX1 exon 3, XPD exon 6, and GSTT1 polymorphism, although the ORs in the polymorphism groups remained higher than reference groups.

Subsequently, we performed gene-gene interaction separately for different groups with the adjustment for age, gender, cumulative arsenic exposure, and MMA percentage ([Table 5](#tab5){ref-type="table"}). Among the xenobiotic metabolic genes (GST family), ORs in the 1-, 2-, and 3-polymorphism groups as compared to the 0-polymorphism group were 4.21 (1.38--12.85), 4.61 (1.52--13.98), and 3.58 (1.00--12.79), respectively (data not shown). When more than or equal to one polymorphism group was combined, the OR became 4.27 (1.48--12.38). Among the ROS-related metabolic genes, we chose NQO1, HO-1, and EPHX1 exon 3. In comparison to the referent group with less than two polymorphisms, ORs of the 2- and 3-polymorphism groups were 1.68 (0.86--3.26) and 1.88 (0.69--5.13), respectively. The *P* values of the two groups did not demonstrate significance. In the analysis of polymorphisms in DNA repair genes, we chose XPD, hOGG1, ATM, and XRCC1 exon 9. No significant differences were found in the 3- and 4-polymorphism groups compared to the group with less than 3 polymorphisms; the ORs were 4.40 (0.57--34.26) and 6.95 (0.86--56.23), respectively. However, the *P* value for trend was statistically significant (*P* = 0.0334).

Finally, we investigated the gene-gene interactions of GST genes, EPHX1 exon 3, and XPD exon 6, which showed significant differences between cases and controls in univariate analysis. When the groups with less than 2 polymorphisms were combined as a reference, the ORs of the 2- and 3-polymorphism groups were 1.56 (0.32--7.45) and 4.86 (1.08--21.85), respectively, while the *P* value for the trend was 0.0004. Moreover, we found significantly higher disease risk among the 3-polymorphism group, with a *P* value of 0.0392.

4. Discussion {#sec4}
=============

In the present study, we analyzed 12 polymorphisms in 10 genes in an established population in Taiwan. A total of 70 cases and 210 healthy control individuals were included in this study. Similar to previous studies, the subpopulation with higher cumulative arsenic exposure had a higher risk in developing arsenic-induced skin cancer \[[@B26]--[@B28]\]. Although the group having a high MMA percentage also had a higher OR, the data was not completely comparable to former case control studies on arsenic-induced skin cancer. In one report, which used the same study participants as our present study, the OR was 23.96 (2.55--225.2) for the study participants who had cumulative arsenic exposure of more than 20 mg/liter × year and MMA percentage of more than 26.7% \[[@B28]\]. In addition, Yu et al. showed that the OR in the group with MMA percentage higher than 15.5% was 5.52 (1.22--24.81), as compared to the group with MMA percentage of less than 15.5% \[[@B29]\]. Nevertheless, our data presented no significance when grouped by 26.7% and 15.5%, and the ORs were 1.10 (0.51--2.37) and 1.43 (0.79--2.61), respectively (data not shown). However, when we grouped the participants by 13.81%, which was the median value of the control group, the OR in the high MMA percentage group became 2.01 (1.09--3.73) and as a result showed significance.

The polymorphisms analyzed in this study have been investigated for their roles in various diseases. In the GST group, the GSTM1 subtype was reported to correlate with cervical neoplasia and chronic obstructive pulmonary disease \[[@B30], [@B31]\], while GSTT1 subtype had a higher incidence or percentage of bladder cancer \[[@B32]\] and the GSTP1 Ile105Val polymorphism was related with squamous cell carcinoma (SCC) and colorectal cancer \[[@B33], [@B34]\]. NQO1 C609T was reported in many diseases, including lung cancer, bladder cancer, and esophageal squamous cell carcinoma \[[@B33], [@B35], [@B36]\]. Both EPHX1 polymorphisms in Tyr113His and His139Arg revealed significantly high risks in developing lung cancer and polycystic ovary syndrome \[[@B37], [@B38]\]. Furthermore, the correlation between the long HO-1 (GT) repeat and oral squamous cell carcinoma has been identified \[[@B39]\]. Among DNA repair genes, XRCC1 Arg399Gln has been reported in breast cancer and skin cancer \[[@B16], [@B40]\], while XPD C156A was correlated with basal cell carcinoma \[[@B41]\], and the hOGG1 Ser326Cys polymorphism has been studied as a causal factor in lung and esophageal cancers \[[@B20], [@B42], [@B43]\].

In the univariate analysis, GSTT1 genotype, EPHX1 Tyr113His, and XPD C156A polymorphisms showed significant differences between skin cancer patients and controls. After considering age, gender, cumulative arsenic exposure, and MMA percentage, none of the SNPs showed significant association with the disease risk. We suggest that this may be because the effect of arsenic was too strong and, therefore, the genetic effect was overshadowed after adjustments were made for two arsenic-correlated parameters. Gene-gene interactions conducted in different pathways showed different results. In the xenobiotic metabolic genes GSTs, there was a significant increase in equal to or more than 1-risk-polymorphism groups when compared to the 0-risk group, with a *P* value of 0.0074. These results indicated that the GST polymorphisms may exert strong effects in arsenic-induced skin cancer. ROS-related gene polymorphisms showed no significant differences in the 2- and 3-polymorphism groups compared to the group with less than 2 polymorphisms. On the other hand, a higher risk polymorphism number of DNA repair genes were associated with an increased disease risk, and test for trend was statistically significant. When considering GST family genes, EPHX1 Tyr113His and XPD C156A together, we found that the higher the polymorphism number among these genes, the higher the risk for skin cancer development. Test for trend was also statistically significant even considering multiple comparison issue. Compared to the referent group with less than 2 polymorphisms, the 2-polymorphism group did not show any significant differences, though the 3-polymorphism group showed significant increase in OR (4.67). These results indicated that participants who had 3 polymorphisms would have higher risks than the group with less than 1 polymorphism in developing arsenic-induced skin cancer.

Although we identified some changes in the gene-gene interaction analysis, there was no satisfactorily significant increase in OR values in the present study. Possible explanations may include the following: (i) carcinogenesis is known to be a multistep process, and perhaps any one or few of these genes were not sufficient in their effects in tumor formation; (ii) the polymorphisms were chosen from previous studies that reportedly correlated with diseases, but there might be alternative or additional genes that are more crucial in the development of arsenic-induced skin cancer. For example, when considering the association of ROS genes with skin cancer, we did not include catalase or superoxide dismutase in the present study; (iii) many of the genes in this study belonged to different pathways involved in cellular activities and therefore their corresponding effects and impact might not be in concert. Another potential issue was the inherent limitation in the sample size, which only included a study population of 280 participants. It appears that this sample size was insufficient, especially during analysis of gene-gene interactions, where we were compelled to combine two or three groups to calculate the OR values because case numbers were too few in some groups. Furthermore, we were unfortunately unable to obtain all available data on cumulative arsenic exposure and MMA percentage, as the possession of complete information would no doubt influence the results in adjustment and further analysis.

In conclusion, we suggest that GSTT1, EPHX1 Tyr113His, and XPD C156A polymorphisms are potential genetic factors for arsenic-induced skin carcinogenesis. Individuals who carried all the 3 risk polymorphisms, including any risk variant of GSTs, EPHX1 Tyr113His, and XPD C156A polymorphisms, had a 4.86-fold risk for the development of arsenic-related skin cancers compared to those with less than 2 polymorphisms. Genes that are even more critical and are involved in arsenic-induced skin cancers remain to be identified and investigated.

The study was funded by the National Science Council, Executive Yuan, Taipei, Taiwan (Grant nos. NSC100-2314-B-001-006-MY3, NSC100-2314-B-001-004-MY3, and MOST 103-2314-B-001-006-).

Conflict of Interests
=====================

The authors declare that there is no conflict of interests regarding the publication of this paper.

###### 

PCR primers and restriction enzymes of selected polymorphisms.

  Gene                                 Primer                              Enzyme
  ------------------------------------ ----------------------------------- ---------
  *GSTM1*                              Forward: GAACTCCCTGAAAAGCTAAAGC      
  Reverse: GTTGGGCTCAAATATACGGTGG                                          
                                                                           
  *GSTT1*                              Forward: TTCCTTACTGGTCCTCACATCTC     
  Reverse: CAGCTGCATTTGGAAGTGCTC                                           
                                                                           
  *GSTP1* (Ile105Val, rs1695)          Forward: GTAGTTTGCCCAAGGTCAAG       BsmAI
  Reverse: AGCCACCTGAGGGGTAAG                                              
                                                                           
  *NQO1* (C609T, rs1800566)            Forward: AAGCCCAGACCAACTTCT         HinfI
  Reverse: ATTTGAATTCGGGCGTCTGCTG                                          
                                                                           
  *EPHX1* (Tyr113His, rs1051740)       Forward: CTTGAGCTCTGTCCTTCCCATCCC   Tth111I
  Reverse: AATCTTAGTCTTGAAGTGACGGT                                         
                                                                           
  *EPHX1* (His139Arg, rs2234922)       Forward: ACATCCACTTCATCCACGT        Rsa1
  Reverse: ATGCCTCTGAGAAGCCAT                                              
                                                                           
  *HO-1* (5′-site GT repeats)          Forward: FAM-AGAGCCTGCAGCTTCTCAGA    
  Reverse: ACAAAGTCTGGCCATAGGAC                                            
                                                                           
  *XRCC1* (Arg280His, rs25489)         Forward: GGCTGGGACCACCTGTGTT        RsaI
  Reverse: TTGACCCCCAGTGGTGCTAA                                            
                                                                           
  *XRCC1* (Arg399Gln, rs25487)         Forward: TCTCCCTTGGTCTCCAACCT       MspI
  Reverse: AGTAGTCTGCTGGCTCTGG                                             
                                                                           
  *XPD* (C156A, rs238406)              Forward: TGGAGTGCTATGGCACGATCTCT    TflI
  Reverse: CCATGGGCATCAAATTCCTGGGA                                         
                                                                           
  *hOGG1* (Ser326Cys, rs1052133)       Forward: ACTGTCACTAGTCTCACCAG       Fnu4HI
  Reverse: TGAATTCGGAAGGTGCTTGGGGAAT                                       
                                                                           
  *ATM* (INV48 +238C\>G, rs609429)     Forward: CCTGGTTATAAAATGAGAAGG      KpnI
  Reverse: GCAGCAACTACCATTCATTGAG                                          

###### 

Distribution of demographic variables, arsenic exposure level, and percentage of monomethylarsonic acid (MMA) between skin cancer cases and age and sex matched controls.

  --------------------------------------------------------------------------------------------------------------------------------
  Variable             Group                    Case           Control        OR (95% CI)                             
  -------------------- ------------------------ -------------- -------------- ------------- --------- --------------- ------------
  Age                  (Mean ± Std deviation)   56.13 ± 6.87   54.38 ± 6.26                                           

                                                                                                                      

  Gender               Male                     46             (65.71)        138           (65.71)                    

  Female               24                       (34.29)        72             (34.29)                                 

                                                                                                                      

  Cumulative\          \<10.0                   4              (5.71)         40            (19.05)   1.00            (Referent)
  as exposure\                                                                                                        
  (ppm-year)                                                                                                          

  10.0--19.9           22                       (31.43)        62             (29.52)       3.55      (1.14--11.06)   

  20.0+                31                       (44.29)        59             (28.10)       5.25      (1.72--16.05)   

  Unknown              13                       (18.57)        49             (23.33)       2.65      (0.80--8.77)    

                                                                                                                      

  MMA percentage (%)   0--13.81                 21             (30.00)        94            (44.76)   1.00            (Referent)

  13.81+               36                       (51.43)        80             (38.10)       2.01      (1.09--3.73)    

  Unknown              13                       (18.57)        36             (17.14)       1.61      (0.73--3.57)    
  --------------------------------------------------------------------------------------------------------------------------------

###### 

Univariate analysis of genetic polymorphisms in glutathione S-transferase family, reactive oxidative stress genes, and DNA repair genes.

  Gene                               Case   Control   OR (95% CI)   *P* value                                                
  ---------------------------------- ------ --------- ------------- ----------- ------ --------------- ------ -------------- ------
  *GSTM1*                                                                                                                     
  Nonnull                            25     (35.71)   86            (41.15)     1.00   (Referent)                            0.42
  Null                               45     (64.29)   123           (58.85)     1.26   (0.72--2.21)                          
                                                                                                                             
  *GSTT1*                                                                                                                     
  Nonnull                            27     (38.57)   109           (52.15)     1.00   (Referent)                            0.05
  Null                               43     (61.43)   100           (47.85)     1.74   (1.00--3.02)                          
                                                                                                                             
  *GSTP1*(Ile105Val, rs1695)                                                                                                  
  W/W                                44     (62.86)   143           (68.10)     1.00   (Referent)      1.00   (Referent)     0.42
  W/M                                26     (37.14)   59            (28.10)     1.47   (0.83--2.61)    1.26   (0.72--2.22)   
  M/M                                0      ---       8             (3.81)      ---    ---                                   
                                                                                                                             
  *NQO1*(C609T, rs1800566)                                                                                                    
  C/C                                18     (26.47)   70            (35.00)     1.00   (Referent)      1.00   (Referent)     0.19
  C/T                                36     (52.94)   104           (52.00)     1.35   (0.71--2.56)    1.50   (0.81--2.76)   
  T/T                                14     (20.59)   26            (13.00)     2.09   (0.91--4.81)                          
                                                                                                                             
  *EPHX1*(Tyr113His, rs1051740)                                                                                               
  T/T                                4      (6.15)    31            (16.40)     1.00   (Referent)      1.00   (Referent)     0.04
  T/C                                27     (41.54)   56            (29.63)     3.74   (1.20--11.66)   2.99   (1.01--8.83)   
  C/C                                34     (52.31)   102           (53.97)     2.58   (0.85--7.85)                          
                                                                                                                             
  *EPHX1* (His139Arg, rs2234922)                                                                                              
  G/G                                0      ---       4             (1.94)      1.00   (Referent)                            0.49
  A/G                                15     (22.06)   50            (24.27)                                                  
  A/A                                53     (77.94)   152           (73.79)     0.80   (0.42--1.53)                          
                                                                                                                             
  *HO-1* (5′-site GT repeats)                                                                                                 
  L/L                                17     (26.15)   47            (23.62)     1.00   (Referent)                            0.87
  S/L                                34     (52.31)   111           (55.78)                                                  
  S/S                                14     (21.54)   41            (20.60)     1.06   (0.53--2.10)                          
                                                                                                                             
  *XRCC1* (Arg280His, rs25489)                                                                                                
  His/His                            0      ---       4             (1.93)      1.00   (Referent)                            0.16
  Arg/His                            9      (13.04)   39            (18.84)                                                  
  Arg/Arg                            60     (86.96)   164           (79.23)     1.75   (0.80--3.80)                          
                                                                                                                             
  *XRCC1* (Arg399Gln, rs25487)                                                                                                
  Arg/Arg                            35     (50.72)   114           (55.34)     1.00   (Referent)      1.00   (Referent)     0.50
  Arg/Gln                            26     (37.68)   71            (34.47)     1.19   (0.66--2.15)    1.20   (0.70--2.08)   
  Gln/Gln                            8      (11.59)   21            (10.19)     1.24   (0.51--3.05)                          
                                                                                                                             
  *XPD* (C156A, rs238406)                                                                                                     
  CC                                 10     (14.93)   54            (26.34)     1.00   (Referent)      1.00   (Referent)     0.05
  AC                                 40     (59.70)   110           (53.66)     1.96   (0.91--4.22)    2.04   (0.99--4.27)   
  AA                                 17     (25.37)   41            (20.00)     2.24   (0.93--5.40)                          
                                                                                                                             
  *hOGG1* (Ser326Cys, rs1052133)                                                                                              
  Cys/Cys                            22     (32.35)   82            (39.42)     1.00   (Referent)      1.00   (Referent)     0.30
  Ser/Cys                            37     (54.41)   103           (49.52)     1.34   (0.73--2.45)    1.36   (0.76--2.43)   
  Ser/Ser                            9      (13.24)   23            (11.06)     1.46   (0.59--3.60)                          
                                                                                                                             
  *ATM* (INV48 +238C\>G, rs609429)                                                                                            
  CC                                 21     (36.21)   77            (37.75)     1.00   (Referent)      1.00   (Referent)     0.84
  CG                                 26     (44.83)   89            (43.63)     1.07   (0.56--2.05)    1.07   (0.58--1.95)   
  GG                                 11     (18.97)   38            (18.63)     1.06   (0.46--2.42)                          

###### 

Multivariate analysis of genetic polymorphisms in glutathione S-transferase family, reactive oxidative stress genes, and DNA repair genes.

  Gene                               Case   Control   OR (95% CI)   *P* value                                                
  ---------------------------------- ------ --------- ------------- ----------- ------ --------------- ------ -------------- ------
  *GSTM1*                                                                                                                     
  Nonnull                            25     (35.71)   86            (41.15)     1.00   (Referent)                            0.46
  Null                               45     (64.29)   123           (58.85)     1.26   (0.68--2.39)                          
                                                                                                                             
  *GSTT1*                                                                                                                     
  Nonnull                            27     (38.57)   109           (52.15)     1.00   (Referent)                            0.30
  Null                               43     (61.43)   100           (47.85)     1.36   (0.76--2.46)                          
                                                                                                                             
  *GSTP1*(Ile105Val, rs1695)                                                                                                  
  W/W                                44     (62.86)   143           (68.10)     1.00   (Referent)      1.00   (Referent)     0.56
  W/M                                26     (37.14)   59            (28.10)     1.17   (0.57--2.37)    1.21   (0.64--2.30)   
  M/M                                0      ---       8             (3.81)      ---    ---                                   
                                                                                                                             
  *NQO1*(C609T, rs1800566)                                                                                                    
  C/C                                18     (26.47)   70            (35.00)     1.00   (Referent)      1.00   (Referent)     0.41
  C/T                                36     (52.94)   104           (52.00)     1.08   (0.51--2.29)    1.33   (0.68--2.58)   
  T/T                                14     (20.59)   26            (13.00)     2.12   (0.77--5.86)                          
                                                                                                                             
  *EPHX1*(Tyr113His, rs1051740)                                                                                               
  T/T                                4      (6.15)    31            (16.40)     1.00   (Referent)      1.00   (Referent)     0.07
  T/C                                27     (41.54)   56            (29.63)     3.25   (1.01--10.54)   2.71   (0.90--8.25)   
  C/C                                34     (52.31)   102           (53.97)     2.32   (0.74--7.31)                          
                                                                                                                             
  *EPHX1* (His139Arg, rs2234922)                                                                                              
  G/G                                0      ---       4             (1.94)      1.00   (Referent)                            0.35
  A/G                                15     (22.06)   50            (24.27)                                                  
  A/A                                53     (77.94)   152           (73.79)     0.71   (0.35--1.48)                          
                                                                                                                             
  *HO-1* (5′-site GT repeats)                                                                                                 
  L/L                                17     (26.15)   47            (23.62)     1.00   (Referent)                            0.45
  S/L                                34     (52.31)   111           (55.78)                                                  
  S/S                                14     (21.54)   41            (20.60)     0.94   (0.42--2.08)                          
                                                                                                                             
  *XRCC1* (Arg280His, rs25489)                                                                                                
  His/His                            0      ---       4             (1.93)      1.00   (Referent)                            0.39
  Arg/His                            9      (13.04)   39            (18.84)                                                  
  Arg/Arg                            60     (86.96)   164           (79.23)     0.69   (0.28--1.62)                          
                                                                                                                             
  *XRCC1* (Arg399Gln, rs25487)                                                                                                
  Arg/Arg                            35     (50.72)   114           (55.34)     1.00   (Referent)      1.00   (Referent)     0.76
  Arg/Gln                            26     (37.68)   71            (34.47)     1.18   (0.57--2.43)    1.11   (0.59--2.07)   
  Gln/Gln                            8      (11.59)   21            (10.19)     0.90   (0.30--2.66)                          
                                                                                                                             
  *XPD* (C156A, rs238406)                                                                                                     
  CC                                 10     (14.93)   54            (26.34)     1.00   (Referent)      1.00   (Referent)     0.17
  AC                                 40     (59.70)   110           (53.66)     1.60   (0.72--3.55)    1.71   (0.79--3.69)   
  AA                                 17     (25.37)   41            (20.00)     2.06   (0.82--5.19)                          
                                                                                                                             
  *hOGG1* (Ser326Cys, rs1052133)                                                                                              
  Cys/Cys                            22     (32.35)   82            (39.42)     1.00   (Referent)      1.00   (Referent)     0.41
  Ser/Cys                            37     (54.41)   103           (49.52)     1.16   (0.57--2.37)    0.77   (0.41--1.45)   
  Ser/Ser                            9      (13.24)   23            (11.06)     1.17   (0.38--3.63)                          
                                                                                                                             
  *ATM* (INV48 +238C\>G, rs609429)                                                                                            
  CC                                 21     (36.21)   77            (37.75)     1.00   (Referent)      1.00   (Referent)     0.81
  CG                                 26     (44.83)   89            (43.63)     1.08   (0.49--2.34)    1.08   (0.57--2.08)   
  GG                                 11     (18.97)   38            (18.63)     1.44   (0.57--3.69)                          

OR adjusted for age, gender, cumulative arsenic exposure, and monomethylarsonic acid (MMA) percentage.

###### 

Combination analysis of the polymorphisms with skin cancers in the groups of xenobiotic metabolic genes, reactive oxidative stress genes, DNA repair genes, and three highly risk polymorphisms.

  Genotype                                                                                                                                          Case   Control   Multivariate-adjusted   *P* value for trend                          
  ------------------------------------------------------------------------------------------------------------------------------------------------- ------ --------- ----------------------- --------------------- ------ --------------- --------
  Xenobiotic metabolic genes                                                                                                                                                                                                              
  Wild types: *GSTM1* nonnull, *GSTT1* nonnull, *GSTP1* (Ile105Val) W/W                                                                                                                                                                   
   0 polymorphisms                                                                                                                                  4      (5.71)    43                      (20.57)               1.00   (Referent)      0.0074
   1 polymorphism                                                                                                                                   27     (38.57)   69                      (33.01)               4.27   (1.48--12.38)   
   2 polymorphisms                                                                                                                                  30     (42.86)   70                      (33.50)                                      
   3 polymorphisms                                                                                                                                  9      (12.86)   27                      (12.92)                                      
                                                                                                                                                                                                                                          
  Reactive oxidative stress genes                                                                                                                                                                                                         
  Wild types: *NQO1* (C609T) C/C, *EPHX* (Tyr113His) T/T, *HO-1*(5′-site GT repeats) L/L & S/L                                                                                                                                            
   0 polymorphisms                                                                                                                                  1      (1.59)    7                       (4.02)                1.00   (Referent)      0.12
   1 polymorphism                                                                                                                                   15     (23.81)   57                      (32.76)                                      
   2 polymorphisms                                                                                                                                  39     (61.90)   93                      (53.45)               1.68   (0.86--3.26)    
   3 polymorphisms                                                                                                                                  8      (12.70)   17                      (9.77)                1.88   (0.69--5.13)    
                                                                                                                                                                                                                                          
  *DNA repair genes*                                                                                                                                                                                                                      
  Wild types: *XRCC1* (Arg280His) His/His & His/Arg, *XPD* (C156A) C/C, *hOGG1* (Ser326Cys) Cys/Cys, *ATM* (INV48 +238C\>G) C/C   *  *                                                                                                    
   0 polymorphisms                                                                                                                                  1      (1.85)    1                       (0.51)                1.00   (Referent)      0.0334
   1 polymorphism                                                                                                                                   0      ---       16                      (8.16)                                       
   2 polymorphisms                                                                                                                                  15     (27.78)   60                      (30.61)                                      
   3 polymorphisms                                                                                                                                  20     (37.04)   75                      (38.27)               4.40   (0.57--34.26)   
   4 polymorphisms                                                                                                                                  18     (33.33)   44                      (22.45)               6.95   (0.86--56.23)   
                                                                                                                                                                                                                                          
  Three highly risk polymorphisms                                                                                                                                                                                                         
  Wild types: no risk polymorphism of the *GST*s (*GSTM1* nonnull, *GSTT1* nonnull, *GSTP1* W/W), *EPHX1* (Tyr113His) T/T, *XPD* (C156A)  *   *                                                                                           
  C/C                                                                                                                                                                                                                                     
   0 polymorphisms                                                                                                                                  0      ---       2                       (1.08)                1.00   (Referent)      0.0004
   1 polymorphism                                                                                                                                   2      (3.17)    16                      (8.60)                                       
   2 polymorphisms                                                                                                                                  14     (22.22)   81                      (43.55)               1.56   (0.32--7.45)    
   3 polymorphisms                                                                                                                                  47     (74.60)   87                      (46.77)               4.86   (1.08--21.85)   

ROS: reactive oxidative stress.

[^1]: Academic Editor: Marian K. Malde
